-
Mashup Score: 0Dupilumab Effective Against Prurigo Nodularis Out to 6 Months - 2 month(s) ago
Dupilumab (Dupixent) improved itch and skin lesions compared with placebo in people with prurigo nodularis (PN), according to a study in . The data, from a pair of phase 3 trials known as LIBERTY-PN PRIME and PRIME 2, came from adults with PN who had ≥20 nodules and severe itch that had not been adequately controlled by topical therapies.
Source: www.medpagetoday.comCategories: General Medicine News, General HCPsTweet
ICYMI: What does the foreseeable future hold for #dupilumab and dupilumab research? #AADReadingRoom @AADskin #dermatology Read more: https://t.co/ZinSuXO9t2 https://t.co/vi5b0s5GJc